Analyzing Guardant Health (GH) and Its Competitors

Share on StockTwits

Guardant Health (NASDAQ: GH) is one of 24 public companies in the “Medical laboratories” industry, but how does it weigh in compared to its rivals? We will compare Guardant Health to similar businesses based on the strength of its risk, earnings, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Guardant Health and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Guardant Health 0 0 5 0 3.00
Guardant Health Competitors 178 637 745 46 2.41

Guardant Health currently has a consensus price target of $79.67, suggesting a potential upside of 7.63%. As a group, “Medical laboratories” companies have a potential upside of 15.77%. Given Guardant Health’s rivals higher possible upside, analysts clearly believe Guardant Health has less favorable growth aspects than its rivals.

Valuation & Earnings

This table compares Guardant Health and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Guardant Health $90.64 million -$85.06 million -26.44
Guardant Health Competitors $1.13 billion $64.04 million -2.11

Guardant Health’s rivals have higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

69.5% of Guardant Health shares are held by institutional investors. Comparatively, 52.0% of shares of all “Medical laboratories” companies are held by institutional investors. 17.1% of shares of all “Medical laboratories” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Guardant Health and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Guardant Health N/A N/A N/A
Guardant Health Competitors -108.16% -113.88% -33.85%

Guardant Health Company Profile

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Mao Zedong  Price Hits $0.0533
Mao Zedong Price Hits $0.0533
ECC  Price Tops $0.0002 on Top Exchanges
ECC Price Tops $0.0002 on Top Exchanges
WIZBL Price Up 5.8% Over Last Week
WIZBL Price Up 5.8% Over Last Week
YOYOW 24 Hour Trading Volume Hits $623,320.00
YOYOW 24 Hour Trading Volume Hits $623,320.00
$240.47 Million in Sales Expected for Golden Entertainment Inc  This Quarter
$240.47 Million in Sales Expected for Golden Entertainment Inc This Quarter
Brokerages Expect Northfield Bancorp Inc  to Announce $0.19 EPS
Brokerages Expect Northfield Bancorp Inc to Announce $0.19 EPS


 
© 2006-2019 Zolmax.